Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo.

Abstract

Alzheimer's disease (AD) is characterized, amongst others, by the appearance of vascular and parenchymal beta-amyloid deposits in brain. Such aggregates are mainly composed of beta-amyloid peptides, which are derived by proteolytic processing of a larger amyloid precursor protein (APP). APP is highly conserved among mammalian species, but experimental studies in rodents are often hampered by the humble APP-processing in the amyloidogenic pathway and by the inability of rodent beta-amyloid peptides to form higher molecular aggregates such as soluble oligomers and insoluble beta-amyloid plaques. Thus, there is need for in vitro and in vivo model systems that allow identification of factors that increase amyloidogenic APP processing and accelerate beta-amyloid plaque formation and testing the potency of pharmacological manipulations to ameliorate beta-amyloid load in brain. Transgenic mice that overexpress human APP containing AD-associated mutations that favor the amyloidogenic pathway of APP processing represent such a model. However, mutations of the APP gene are not frequent in AD and, therefore, the mechanisms of beta-amyloid plaque formation, the composition of beta-amyloid plaques, and the accompanying tissue response in brain of these animals may be different from that in AD. In contrast, guinea pigs express beta-amyloid peptides of the human sequence and appear to represent a more physiological model to examine the long-term effects of experimental manipulations on APP processing and beta-amyloid plaque formation in vivo. Additionally, APP processing in guinea pig primary neuronal cultures has been shown to be similar to cultures of human origin. In this article we highlight the advantages and limitations of using guinea pigs as experimental models to study APP processing.